Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Confo Therapeutics: Drugging the Undruggable

Llama single-domain antibodies have found yet another application, one that Confo Therapeutics is fully exploiting. Ablynx is developing Nanobodie…


The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects difficult to f…


Sammson gene causes melanoma

In collaboration with big N2N researchers from UGent, VIB scientists from KU Leuven have revealed a remarkable link between malignant melanoma and…

POPULAR TAGS

Prof. Carmeliet as Chief Scientific Strategy Advisor at Oncurious

Written by DS on in the category news with the tags , , , .


Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor. Oncurious is a new oncology company and a joint venture between ThromboGenics NV and VIB, a leading life sciences institute in Flanders (Belgium).

Since 15 years Prof Carmeliet (VIB Vesalius Research Center, KU Leuven) has focused his research interests on unravelling the molecular basis of neuro-vascular biological processes and diseases, and translating these genetic insights into therapeutic concepts – with the ultimate aspiration to develop novel treatments.

Research conducted by Prof Carmeliet’s team at VIB/KU Leuven, in collaboration with Prof Rakesh Jain from the Massachusetts General Hospital at Harvard (Boston), generated the first pre-clinical data on the use of human monoclonal antibodies against placental growth factor (PlGF) in the treatment of medulloblastoma. Based on the positive results, TB-403 will be now further developed by Oncurious for the treatment of pediatric tumors.

Prof Dr Peter Carmeliet comments: “I am pleased with this opportunity to support the translation of pre-clinical research conducted at VIB/KU Leuven and other world leading institutes into potential novel cancer treatments. Working with Oncurious NV gives me the occasion to remain very closely involved in the process of developing a drug for clinical use.”

Dr Patrik De Haes, CEO of ThromboGenics NV and Executive Chairman of Oncurious NV: "We are delighted that Prof Carmeliet has accepted the role of Chief Scientific Strategy Advisor with Oncurious. Professor Carmeliet is a globally renowned leader in the field of oncology research and its underlying biological processes. His scientific insights, research and in-depth expertise will be very valuable as the Oncurious team progresses its current clinical development of TB-403 for the treatment of pediatric brain tumors, I am confident that his insights will, in time, allow Oncurious to build an oncology pipeline and become an international leader in developing novel cancer therapies.”

(Source: VIB)

Read more about: , , , .

RELATED ARTICLES
Confo Therapeutics: Drugging the Undruggable

Llama single-domain antibodies have found yet another application, one that Confo Therapeutics is fully exploiting. Ablynx is developing Nanobodie…


The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects difficult to f…


Sammson gene causes melanoma

In collaboration with big N2N researchers from UGent, VIB scientists from KU Leuven have revealed a remarkable link between malignant melanoma and…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Flanders.bio XpandInnovation KU Leuven UGent Turnstone Janssen Itera Life Science Biowin GSK V-Bio Ventures

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.